ZURA

NASDAQ open

Zura Bio

0.95 USD
▼-0.01-0.73%
盘后 3.79 0.00%
2026-11-20
市值
$89.63M
市盈率
—
EPS
-1.06
股息率
—
52 周区间
0.92 – 7.44
成交量
2.30M
Beta
0.02
目标价
8.00
52W 低 0.9252W 高 7.44
价格走势

公司简介

Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development. It also develops Torudokimab (ZB-880), a fully human immunoglobulin G4 monoclonal antibody targeting interleukin-33 that has completed Phase 1 clinical studies; and C...

关联新闻

  • Zura Bio's skin disease drug fails mid-stage trial

    Zura Bio said on Monday its experimental drug failed the main goal of a mid-stage study in ​patients with hidradenitis suppurativa, a chronic skin disease ‌that causes painful lumps under the skin.

    Reuters2026-11-09ZURA